Experience of anti-Immunoglobulin E-therapy in children with chronic inducible urticaria
- 作者: Larkova I.1,2, Revyakina V.1,2
-
隶属关系:
- Federal Research Center of Nutrition, Biotechnology and Food Safety
- National Medical Research Center for Children’s Health
- 期: 卷 18, 编号 4 (2021)
- 页面: 135-139
- 栏目: Case reports
- URL: https://journals.rcsi.science/raj/article/view/121703
- DOI: https://doi.org/10.36691/RJA1467
- ID: 121703
如何引用文章
全文:
详细
Based on clinical cases, the authors present their own experience of successful anti-Immunoglobulin E-therapy using omalizumab at 300 mg every 4 weeks with clinical manifestations of chronic inducible urticaria in children, such as cholinergic urticaria and cold urticaria, which was observed without chronic spontaneous urticaria symptoms. Concurrently, the patient with cold urticaria had a complete response after the first injection, with a total course of treatment of 6 months, whereas the patient with cholinergic urticaria did not immediately receive therapy and needed a 12-month course of treatment with strict administration regimen adherence for 4 weeks. All patients have achieved sustained disease remission.
作者简介
Inna Larkova
Federal Research Center of Nutrition, Biotechnology and Food Safety; National Medical Research Center for Children’s Health
编辑信件的主要联系方式.
Email: inna_larkova@mail.ru
ORCID iD: 0000-0001-7640-0754
SPIN 代码: 2991-3774
MD, Cand. Sci. (Med.)
俄罗斯联邦, 21 Kashirskoye shosse, 115446 Moscow; MoscowVera Revyakina
Federal Research Center of Nutrition, Biotechnology and Food Safety; National Medical Research Center for Children’s Health
Email: 5356797@mail.ru
ORCID iD: 0000-0002-1149-7927
SPIN 代码: 4607-0540
MD, Cand. Sci. (Med.)
俄罗斯联邦, 21 Kashirskoye shosse, 115446 Moscow; Moscow参考
- Russian Association of Allergists and Clinical Immunologists. Moscow: Federal Clinical Guidelines for the Diagnosis and Treatment of Urticaria; 2019. 57 р. (In Russ).
- Zuberbier T, Aberer W, Asero R, еt al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. doi: 10.1111/all.13397
- Sánchez J, Amaya E, Acevedo A, еt al. Prevalence of inducible urticaria in patients with chronic spontaneous urticaria: associated risk factors. J Allergy Clin Immunol Pract. 2017;5(2):464–470. doi: 10.1016/j.jaip.2016.09.029
- Silpa-archa N, Kulthanan K, Pinkaew S. Physical urticaria: prevalence, type and natural course in a tropical country. J Eur Acad Dermatol Venereol. 2011;25(10):1194–1199. doi: 10.1111/j.1468-3083.2010.03951
- Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria. J Allergy Clin Immunol Pract. 2018;6(4):1119–1130. doi: 10.1016/j.jaip.2018.03.007
- Kocatürk E, Can PK, Akbas PE, et al. Management of chronic inducible urticaria according to the guidelines: a prospective controlled study. J Dermatol Sci. 2017;87(1):60–69 doi: 10.1016/j.jdermsci.2017.02.283
- Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018;141:638–649. doi: 10.1016/j.jaci.2017.06.032
